Antistax® tablets are used to relieve the symptoms associated with chronic venous insufficiency (CVI Syndrome), in association with varicose veins, including swelling of the lower leg, heavy or tired legs, sensation of tension, tingling and pain.
What Antistax® tablets Contain:
The active substance per tablet is 360 mg of a preparation of dry extract of red vine leaf AS 195 (4 - 6:1), which corresponds to 96 % of dry (pure) extract of red vine leaf and 4 % of colloidal anhydrous silica.
The other ingredients are calcium hydrogen phosphate (anhydrous), crospovidone, croscarmellose sodium, ferric oxide red (E172), glyceryl tristearate, hypromellose, microcrystalline cellulose, magnesium stearate, silica colloidal (anhydrous), talc, titanium dioxide (E171) and water (purified).
None of the ingredients of Antistax® tablets are derived from animal origin.
Do not take Antistax® tablets:
- If you are hypersensitive (allergic) to any of the ingredients in this product. (Refer to "What Antistax® tablets Contain", above.)
Pregnancy and Breast-feeding:
Safety in pregnancy and breast-feeding has not been establised. If you are pregnant or breast-feeding your baby while taking this medicine or in anticipation of taking this medicine, please consult your doctor, pharmacist or other healthcare professional for advice.
COPYRIGHT 2023 – Imperial Market Access Healthcare South Africa (Pty) Limited - ALL RIGHTS RESERVED
ANTISTAX® Active Leg tablets. Reg. no.:48/32.2/1076. Each tablet contains dry extract of red vine leaf AS 195 (4 - 6:1) 360 mg per tablet. For full prescribing information refer to the professional information approved by the South African Health Products Regulatory Authority (SAHPRA).
ANTISTAX® Double Fresh Gel contains Red Vine Leaf Extract. Western herbal. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.
HCR: Imperial Market Access Healthcare SA (Pty) Ltd, 10 Skeen Boulevard, Bedfordview, Gauteng, 2007. Reg. no.: 2006/029994/07.
General contact information: info.mahsa.sm@dpworld.com Tel: 012 621 4300. For any quality or safety related queries, please contact Imperial Quality at Quality.healthcare.sm@dpworld.com or Imperial Medical at pvimperiallogistics@dpworld.com.
References: 1. Antistax PIL 2. Antistax Double Fresh Gel PIL 3. Kiesewetter H. Koscielny J, Kalus U et al. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II): a randomised, double-blind, placebo-controlled trial. Arzneim.-Forsch./Drug Res 2000;50(1):109-117. 4. Kalus U, Koscielny J, Grigorov A et al. Improvement of cutaneous microcirculation and oxygen supply in patients with Chronic Venous Insufficiency by orally administered extract of red vine leaves AS 195: a randomised, double-blind, placebo-controlled, crossover study. Drugs R&D 2004; 5(2): 63-71. 5. Nees S, Weiss DR, Reichenblach-Klinke E et al. Protective Effects of Flavonoids Contained in the Red Vine Leaf on Venular Endothelium against the Attack of Activated Blood Components in vitro. Arzneim.-Forsch./Drug Res. 2003;53(5):330-341. 6. (last accessed 12 December 2023) 7. Francoise Pitsch. Results of the DECIDE survey: appraisal of the predictive value for chronic venous disease of a symptom. Phlebolymphology Vol 18. No. 3. 2011 8. NCBI - WWW Error Blocked Diagnostic (last accessed 13 December 2023) 9. The Epidemiology of Chronic Venous Insufficiency and Varicose Veins by Jennifer L. Beebe-Dimmer, John R Pfeifer, Jennifer S. Engle and David Schottenfeld. March 2005 SAZA.ANTI.19.08.0315